Comparative Pharmacology
Head-to-head clinical analysis: LEQVIO versus REPATHA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LEQVIO versus REPATHA.
LEQVIO vs REPATHA
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Leqvio (inclisiran) is a small interfering RNA (siRNA) that targets proprotein convertase subtilisin/kexin type 9 (PCSK9) mRNA. It inhibits PCSK9 synthesis in hepatocytes, leading to increased LDL receptor expression and reduced plasma LDL-C levels.
PCSK9 inhibitor; binds to proprotein convertase subtilisin/kexin type 9 (PCSK9), preventing PCSK9 from binding to LDL receptors, thereby increasing the number of LDL receptors available to clear LDL cholesterol from the blood.
Adjunct to diet and maximally tolerated statin therapy for treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (ASCVD) who require additional lowering of LDL-C
Heterozygous familial hypercholesterolemia (HeFH)Homozygous familial hypercholesterolemia (HoFH)Primary hyperlipidemia (as an adjunct to diet and maximally tolerated statin therapy in patients who require additional lowering of LDL-C)Prevention of cardiovascular events in patients with established cardiovascular disease
284 mg subcutaneously once, then at 3 months, then every 6 months.
140 mg subcutaneously every 2 weeks or 420 mg subcutaneously once monthly.
None Documented
None Documented
Terminal half-life approximately 4 weeks (26 days), supporting monthly subcutaneous dosing.
Terminal elimination half-life is 11-17 days (mean 14 days) following subcutaneous administration; supports dosing every 2 weeks or monthly. The long half-life is due to low systemic clearance (0.04 L/day) and target-mediated drug disposition.
Inclisiran is metabolized by nucleases to shorter inactive oligonucleotides. It is not a substrate for CYP450 enzymes or drug transporters.
Degraded via general protein catabolism into small peptides and amino acids; not metabolized by cytochrome P450 enzymes.
Renal: negligible intact drug; primarily eliminated via binding to target and subsequent intracellular degradation. Biliary/fecal: not quantified; expected minimal.
Renal excretion is minimal (<1% of administered dose); elimination occurs primarily via binding to target PCSK9 and subsequent degradation, with biliary/fecal excretion of degraded fragments (<5% unchanged in feces).
Extensively bound to PCSK9; not albumin-bound; free fraction <1% when bound to target.
99% bound to serum proteins; primarily to albumin (no specific binding protein identified, but albumin constitutes majority).
47 L (approx 0.6 L/kg), indicating limited extravascular distribution.
Vd is 3.0 L (approx 0.04 L/kg assuming 70 kg), indicating distribution primarily within the vascular compartment and minimal extravascular distribution; consistent with a monoclonal antibody.
Subcutaneous: 80-90%.
Subcutaneous: 80% (absolute bioavailability); intravenous administration is not used clinically.
No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (eGFR <30 mL/min/1.73 m^2).
No dose adjustment required for any degree of renal impairment, including end-stage renal disease.
No dose adjustment required for mild hepatic impairment (Child-Pugh A). Not studied in moderate or severe hepatic impairment (Child-Pugh B or C).
No dose adjustment required for mild or moderate hepatic impairment (Child-Pugh A or B). Not studied in severe hepatic impairment (Child-Pugh C).
Safety and efficacy not established in pediatric patients.
Not approved for use in pediatric patients; safety and efficacy not established.
No specific dose adjustments recommended; clinical studies included patients ≥65 years with no overall differences in safety or efficacy.
No specific dose adjustment necessary. Clinical studies included patients aged 65 years and older, with no overall differences in safety or efficacy observed.
None.
None.
["Hypersensitivity reactions including angioedema and urticaria have been reported.","Injection-site reactions (e.g., erythema, pain, pruritus) are common."]
["Hypersensitivity reactions (e.g., angioedema, urticaria) have been reported; discontinue if severe.","Increases in serum uric acid levels have been observed.","Risk of injection site reactions (e.g., erythema, pain, bruising)."]
["History of serious hypersensitivity reaction to inclisiran or any excipient in Leqvio."]
History of serious hypersensitivity reaction to evolocumab or any excipients.
Data Pending Review
Data Pending Review
No specific food interactions. Take with or without food. Avoid grapefruit juice if also taking statins; however, inclisiran itself has no dietary restrictions.
No known food interactions. However, patients should adhere to a heart-healthy diet low in saturated fats and cholesterol as part of their lipid management plan.
Insufficient human data; animal studies show no evidence of fetal harm. As an siRNA, systemic exposure is low, but administration during pregnancy should only be considered if clearly needed.
No adequate and well-controlled studies in pregnant women. In animal reproduction studies, no evidence of fetal harm was observed at exposures up to 12 times the human exposure at the maximum recommended human dose. However, because animal studies are not always predictive of human response, Repatha should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. There is no risk by trimester specified; generally, caution is advised throughout pregnancy.
Unknown if distributed into human breast milk; no available M/P ratio. Given low bioavailability, risk to nursing infant is likely low, but caution advised.
It is unknown whether evolocumab is excreted in human milk. However, evolocumab is a monoclonal antibody, and monoclonal antibodies are excreted in breast milk in very low concentrations. The M/P ratio is not available. Caution should be exercised when administered to a nursing woman.
No dose adjustment is recommended; pharmacokinetics are not significantly altered in pregnancy based on available data (limited studies). Administer only if potential benefit justifies risk.
No recommended dose adjustment during pregnancy due to lack of data. The pharmacokinetics of evolocumab are not expected to change significantly in pregnancy, as monoclonal antibodies are not metabolized by CYP enzymes and clearance is primarily via FcRn-mediated recycling, which may be altered during pregnancy; however, no specific dose adjustment is currently recommended.
Category C
Category C
Administer subcutaneously; no loading dose required. Monitor for injection site reactions, arthralgia, and urinary tract infections. Do not use in patients with known hypersensitivity to inclisiran. Assess LDL-C levels approximately 90 days after initiation to confirm response.
Repatha (evolocumab) is a PCSK9 inhibitor used as adjunct to diet and maximally tolerated statin for heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (ASCVD). Administer subcutaneously every 2 weeks or monthly. Monitor for injection site reactions and allergic reactions. LDL-C reduction >50% is typical. No dose adjustment needed in renal or hepatic impairment. Avoid in pregnancy unless absolutely necessary.
This medication is given as a subcutaneous injection once every 6 months.Common side effects include injection site reactions (redness, swelling, pain), joint pain, and urinary tract infections.You may need to continue other cholesterol-lowering medications unless your doctor advises otherwise.Report any signs of allergic reaction such as rash, itching, or difficulty breathing.Keep a record of your injection dates. Do not miss scheduled doses.
Inject Repatha subcutaneously in abdomen, thigh, or upper arm; rotate sites.Store in refrigerator (36°F to 46°F) but can be at room temperature up to 30 days.Do not shake the prefilled syringe or autoinjector.Report signs of allergic reaction (rash, hives, difficulty breathing).Continue diet, exercise, and statin therapy as prescribed.Take missed dose within 7 days of scheduled date; if not, skip and resume regular schedule.